Table 1.
Rates of Biomarker Testing Prior to Therapy in Patients with Metastatic NSCLC by Treatment Setting
| Nonsquamous NSCLC | Decisions in Academic Setting (n = 51) | Decisions in Community Setting (n = 253) | Total # of Decisions (N = 304) |
|---|---|---|---|
| ALK Test Status | |||
| Awaiting test results | 6 | 74 | 80 |
| Did not order test | 0 | 19 | 19 |
| Negative | 42 | 157 | 199 |
| Positive | 3 | 3 | 6 |
| ALK testing rate, n (%) | 51 (100) | 234 (92) | 285 (94) |
| EGFR Test Status | |||
| Awaiting test results | 6 | 76 | 82 |
| Did not order test | 0 | 16 | 16 |
| Negative/wild type | 19 | 100 | 119 |
| Non-sensitizing | 7 | 27 | 34 |
| Sensitizing | 19 | 34 | 53 |
| EGFR testing rate, n (%) | 51 (100) | 237 (94) | 288 (95) |
| ROS1 Test Status | |||
| Awaiting test results | 6 | 72 | 78 |
| Did not order test | 0 | 37 | 37 |
| Negative | 43 | 142 | 185 |
| Positive | 2 | 2 | 4 |
| ROS1 testing rate, n (%) | 51 (100)a | 216 (85)a | 267 (88) |
| Nonsquamous and Squamous NSCLC | Decisions in Academic Setting (n = 45) | Decisions in Community Setting (n = 282) | Total # of Decisions (N = 327) b |
| PD-L1 Test Status | |||
| Negative | 15 | 57 | 72 |
| Positive (≥ 50% TPS) | 8 | 55 | 63 |
| Positive (1%−49% TPS) | 5 | 47 | 52 |
| Did not order test | 17 | 123 | 140 |
| PD-L1 testing rate, n (%) | 28 (62) | 159 (56) | 187 (57) |
Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1; TPS, tumor proportion score.
a
P = .0015 for academic vs community settings.
b
Testing data for PD-L1 was not gathered in the first-line setting for part of the analysis period. Data for 69 decisions total (13 in the academic setting, 56 in the community setting) were excluded from the testing rate analysis.